Pharma Industry "Well Positioned" In Current Budget Debate, Avalere's Mendelson Suggests
This article was originally published in The Pink Sheet Daily
Executive Summary
Avalere Health's Dan Mendelson says pharma looks likely to avoid any hits in the budgets being debated for 2011 and 2012, but ideas that would chip away at profits could make a comeback after 2012 elections.
You may also be interested in...
User Fee Waivers For Small Businesses Might Get Smaller Under PDUFA V
FDA wants to tighten its eligibility restrictions for small business waivers of user fees, but industry does not appear interested in changing the rules, even if it would hold down costs for other applicants.
Hamburg Says Generic Drug Reviews Would Slow In Wake Of GOP-Backed Budget Cuts
FDA commissioner predicts poor outlook for medical product review if agency loses appropriations in fiscal 2011 and 2012.
Three Ways IPAB Can Reduce Drug Costs In Medicare: An Interview With Scott Gottlieb
The Independent Payment Advisory Board is likely to take three approaches to reining in drug costs under Medicare, according to American Enterprise Institute Resident Fellow Scott Gottlieb.